Story of claim

Feng Zhang explains CRISPR's role in treating sickle cell anemia by modulating gene expression to induce fetal hemoglobin, reducing symptoms and complexity compared to correcting the mutation directly.

• Goal: To alleviate sickle cell anemia symptoms by inducing fetal hemoglobin expression.
• Proof: Inducing fetal hemoglobin reduces sickle cell symptoms since it doesn't sickle, offering a more feasible treatment than mutation correction.
• Nuances:
  • Fetal hemoglobin naturally reduces sickle cell symptoms.
  • Current treatment is less complex than direct mutation correction.
• Impact on Life: Potentially reduces painful symptoms and decreases the need for regular blood transfusions for patients.